Skip to Content

Varubi Dosage

Generic name: ROLAPITANT HYDROCHLORIDE 90mg
Dosage form: tablet

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Dosage

The recommended dosage of VARUBI tablets and VARUBI injectable emulsion in adults in combination with a 5-HT3 receptor antagonist and dexamethasone for the prevention of nausea and vomiting with emetogenic cancer chemotherapy is shown in Table 1. There is no drug interaction between rolapitant and dexamethasone, so no dosage adjustment for dexamethasone is required. Administer a dexamethasone dose of 20 mg on Day 1 [see Clinical Pharmacology (12.3)].

Administer VARUBI prior to the initiation of each chemotherapy cycle, but at no less than 2 week intervals.

Administer VARUBI tablets without regards to meals.

Table 1: Recommended Dosing Regimen of VARUBI Tablets or VARUBI Injectable Emulsion
Day 1 Day 2 Day 3 Day 4
Prevention of Nausea and Vomiting Associated with Cisplatin-Based Highly Emetogenic Cancer Chemotherapy
VARUBI Administer orally or intravenously within 2 hours prior to initiation of chemotherapy
Oral: 180 mg as a single dose
Injectable emulsion: Infuse 166.5 mg over 30 minutes.
None
Dexamethasone 20 mg; 30 min prior to initiation of chemotherapy 8 mg twice daily 8 mg twice daily 8 mg twice daily
5-HT3 receptor antagonist See the prescribing information for the co-administered 5-HT3 receptor antagonist for appropriate dosing information. None
Prevention of Nausea and Vomiting Associated with Moderately Emetogenic Cancer Chemotherapy and Combinations of Anthracycline and Cyclophosphamide
VARUBI Administer orally or intravenously within 2 hours prior to initiation of chemotherapy
Oral: 180 mg as a single dose
Injectable emulsion: Infuse 166.5 mg over 30 minutes.
None
Dexamethasone 20 mg; 30 min prior to initiation of chemotherapy None
5-HT3 receptor antagonist See the prescribing information for the co-administered 5-HT3 receptor antagonist for appropriate dosing information. See the prescribing information for the co-administered 5-HT3 receptor antagonist for appropriate dosing information.

Instructions for Administration of VARUBI Injectable Emulsion

  • VARUBI injectable emulsion is supplied as a single-dose vial for intravenous administration. The emulsion is homogeneous (no shaking required) and translucent white in appearance.
  • Inspect VARUBI injectable emulsion for particulate matter and discoloration prior to administration; discard if present. Do not use if contamination is suspected.
  • Use and maintain aseptic technique while handling VARUBI injectable emulsion.
  • Administer the dose by inserting a vented intravenous set through the septum of the vial. Once the stopper is punctured, use immediately. Do not dilute VARUBI injectable emulsion.
  • Infuse 92.5 mL from the vial over 30 minutes.
  • VARUBI injectable emulsion is compatible with the following other intravenous fluids through a Y-site connection:
    • Sodium Chloride 0.9% Injection, USP
    • Dextrose 5% Injection, USP
    • Dextrose 5% in Lactated Ringer's Injection, USP
    • Lactated Ringer's Injection, USP
Hide